Target intelligence / Profile preview

NADPH oxidase 2 catalytic subunit (NOX2)

Target
NOX2
Molecular classification
Enzyme, Oxidoreductase, Electron transporter
01

Overview

NADPH oxidase 2 catalytic subunit (NOX2, also known as gp91^phox^) is the principal catalytic component of the phagocyte NADPH oxidase complex. It is a transmembrane flavocytochrome found in neutrophils and other immune cells, where it functions to generate superoxide anion (O_2^–^) by transferring electrons from cytosolic NADPH across the membrane to molecular oxygen. The protein forms a heterodimer with p22^phox^ (the small subunit), together constituting the membrane-bound flavocytochrome b_558_. Activation of the NOX2 complex requires assembly with cytosolic subunits (p47^phox^, p67^phox^, p40^phox^) and a small GTPase Rac1/Rac2, resulting in a rapid "respiratory burst" of superoxide to kill ingested microbes as part of innate immunity[2][3][4][6]. Loss or mutations of gp91^phox^/NOX2 cause chronic granulomatous disease, a rare primary immunodeficiency characterized by severe recurrent infections. Pathological NOX2 activation is also implicated in vascular and inflammatory diseases due to excessive ROS production[3][4]. Drugs such as naloxone and other NOX2 inhibitors are under investigation for their ability to modulate immune and inflammatory responses[5].

Other names
gp91^phox^NOX2Cytochrome b-245 heavy chainBeta subunit of flavocytochrome b_558CYBB (gene name)
02

Mechanism of action

Inhibition of superoxide production via direct interaction with gp91^phox^ subunit (e.g., naloxone)[5]

03

Biological functions

Immune responseGeneration of reactive oxygen species (ROS)Host defense against pathogensElectron transfer
04

Disease associations

Chronic granulomatous diseaseInflammationCardiovascular diseaseInfection
05

Safety considerations

Excessive inhibition may impair host defense and lead to susceptibility to infections (as seen in chronic granulomatous disease)[4]
06

Interacting drugs

Naloxone
07

Biomarkers

Reduced NADPH oxidase (NOX2) activity as a diagnostic marker in chronic granulomatous disease[4]gp91^phox^ protein levels for detecting mutations/deficiency (CGD)[4]

Beyond the preview

Go deeper on NADPH oxidase 2 catalytic subunit (NOX2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADPH oxidase 2 catalytic subunit (NOX2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call